AptarGroup upgraded to Outperform from Neutral at Baird

Baird analyst Ghansham Panjabi upgraded AptarGroup to Outperform from Neutral with a price target of $150, up from $125. The company is executing on a self-improvement phase for its packaging portfolio, “which should nicely complement strong fundamentals in the highly profitable” pharmaceuticals segment, the analyst tells investors in a research note. The firm believes the related acceleration in earnings should combine for outperformance in the shares, noting that AptarGroup is one of the highest quality/defensive franchises within its coverage.